SS-31 (Elamipretide): What the Published Research Reports

SS-31, also referred to as elamipretide, MTP-131, or Bendavia, is a synthetic tetrapeptide with alternating cationic and aromatic residues that a narrative review describes as accumulating in mitochondria and binding cardiolipin in the inner mitochondrial membrane, with reported effects on cristae structure, oxidative stress, and ATP production; that review also catalogues clinical trial programmes conducted in people, including PROGRESS-HF, TAZPOWER, MMPOWER-3, and ReCLAIM [1]. Chemical cross-linking with mass spectrometry in isolated mitochondria identified a set of SS-31 protein interactors, all of them known cardiolipin-binding proteins, clustered around oxidative phosphorylation and 2-oxoglutarate metabolism, with cross-linked residues frequently proximal to cardiolipin-interacting regions [2]. This in vitro interaction mapping is the basis for the mechanistic framing used in most downstream models [2]. In aged mice, elamipretide treatment increased mitochondrial ADP sensitivity in skeletal muscle by increasing ADP uptake through the adenine nucleotide translocator, was accompanied by decreased protein S-glutathionylation including of ANT, and was associated with changes in muscle force and cardiac systolic measures in those animals [3]. A separate proteomic study in mouse hearts reported that ageing increased S-glutathionylation of cysteine residues and that eight weeks of elamipretide treatment largely reversed this shift, with partial effects on age-associated phosphorylation sites [4]. In 24-month-old mice given the peptide for eight weeks, kidney sections showed altered glomerular mitochondrial morphology, reduced glomerulosclerosis, lower senescence markers, and changes in podocyte and endothelial injury markers relative to saline controls [5]. Disease-model work spans several organs, all preclinical. In tafazzin-knockdown mice, a Barth syndrome model, in vivo SS-31 administration was reported to improve mitochondrial respiratory capacity and promote respiratory supercomplex organisation without altering the monolysocardiolipin/cardiolipin ratio [6]. In a rat model of heart failure with preserved ejection fraction, twelve weeks of elamipretide was associated with higher whole-muscle and single-fibre contractile force in soleus and extensor digitorum longus, reduced titin phosphorylation, and prevention of fibre atrophy alongside measures of cardiolipin integrity [7]. In cisplatin-treated mice and in HK-2 cells, SS-31 was reported to lower mitochondrial reactive oxygen species and reduce NLRP3, caspase-1, and IL-1β expression, with corresponding histological and apoptosis changes [8]. In bleomycin-treated mice and in cultured macrophages, SS-31 was associated with reduced fibrotic and inflammatory readouts via an Nrf2-dependent effect on NLRP3 inflammasome activation, an effect absent in Nrf2-knockout animals [9]. Neurological models have also been reported. In mice given lipopolysaccharide, elamipretide treatment was associated with attenuated deficits in Morris water maze and contextual fear conditioning performance, together with changes in hippocampal mitochondrial function, oxidative stress markers, BDNF signalling, and dendritic spine density [10]. In a mouse thoracic contusion model of spinal cord injury, SS-31 was reported to improve locomotor and gait scores, reduce cleaved caspase-3 and Bax while increasing Bcl-2, and to preserve mitochondrial membrane potential and reduce ROS in oxidatively stressed PC12 cells [11]. In pilocarpine-treated rats, SS-31 was associated with reduced hippocampal iron and malondialdehyde, restored Gpx4 and glutathione, and lower p38 MAPK phosphorylation, framed by the authors as inhibition of ferroptosis [12]. Cell-free and cell-based biophysical work reported that SS-31 displaces wild-type and N-terminally acetylated α-synuclein from negatively charged vesicles, alters fibril morphology in thioflavin-T and electron microscopy assays, and restores respiratory parameters in α-synuclein oligomer-treated neuroblastoma cells [13]. Additional in vitro work examined stress models in cardiomyocytes. In H9C2 cardiomyoblasts and human induced pluripotent stem cell-derived cardiomyocytes exposed to γ-radiation, SS-31 reduced senescence-associated β-galactosidase staining, limited increases in p16 and p21, lowered TNF-α, IL-6 and IL-1β, and reversed a radiation-induced rise in mitochondrial respiration [14]. A mitochondria-targeted conjugate of SS-31 with ferrostatin-1 was reported to improve viability and iron-handling and ferroptosis markers in H9C2 cells subjected to hypoxia/reoxygenation [15]. A nanoparticle system using an SS-31 peptide for mitochondrial targeting, combined with insulin, was evaluated in hyperosmotic cell models and in dry eye disease mice, where it altered inflammatory metabolite and cytokine readouts and ocular surface measures [16]. Not all preclinical results were positive: in aged, hypertensive mice, SS-31 treatment did not significantly reduce cerebral microhemorrhage burden, and the study's principal contribution was a machine-learning imaging pipeline for quantifying those lesions [17]. Two narrative reviews summarise the preclinical literature on SS-31 as a mitochondria-targeted antioxidant across models of oxidative stress, inflammation, mitochondrial dynamics, and apoptosis, and in metabolic and neurodegenerative contexts [18][19]. A sports medicine review lists SS-31 among peptides marketed directly to patients and states that, for this class, favourable outcomes in animal models are common while rigorous human safety data remain scarce and regulatory oversight is limited [20].